2. Search Result
Search Result
Results for "

NSD1

" in MedChemExpress (MCE) Product Catalog:

11

Inhibitors & Agonists

1

Antibodies

3

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-134086
    NSD-IN-2
    2 Publications Verification

    		 Histone Methyltransferase Cancer
    NSD-IN-2 is a potent and irreversible NSD inhibitor with inhibitory activity towards members of the NSD family (NSD1/2/3). NSD-IN-2 can be used in research of acute myeloid leukemia [1].
    NSD-IN-2
  • HY-121093
    DC-S239

    		Histone Methyltransferase Cancer
    DC-S239 is a selective histone methyltransferase SET7 inhibitor with an IC50 value of 4.59 μM. DC-S239 also displays selectivity for DNMT1, DOT1L, EZH2, NSD1, SETD8 and G9a. DC-S239 has anticancer activity [1].
    DC-S239
  • HY-114340
    LEM-14

    		Histone Methyltransferase Apoptosis Cancer
    LEM-14 is a potent and selective NSD2 inhibitor with an IC50 of 132 µM. LEM-14 has very weak activitv against NSD1 and has no activity against NSD3. LEM-14 inhibits fibrotic gene expression in ND but not DIO BMDMs. LEM-14 combined with ionizing radiation (IR) enhances the apoptosis rate and reduces the colony-formation ability of CRC cells. LEM-14 exhibits enhanced anti-tumor efficacy in Balb/c nude mice bearing LoVo cell xenografts when combined with ionizing radiation. LEM-14 has the potential for the research of multiple myeloma and colorectal cancer [1] .
    LEM-14
  • HY-125244
    LEM-14-1189

    		Histone Methyltransferase Cancer
    LEM-14-1189, a LEM-14 (HY-114340) derivative, is a NSDs inhibitor with IC50s of 418 μM (NSD1), 111 μM (NSD2), and 60 μM (NSD3), respectively. The NSDs, histone lysine methyltransferases (HMTases), are oncoproteins, drivers of a number of tumors. LEM-14-1189 can be used for multiple myeloma (MM) research [1].
    LEM-14-1189
  • HY-RS18628
    Nsd1 Mouse Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    Nsd1 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Nsd1 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Nsd1 Mouse Pre-designed siRNA Set A
    Nsd1 Mouse Pre-designed siRNA Set A
  • HY-RS09587
    NSD1 Human Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    NSD1 Human Pre-designed siRNA Set A contains three designed siRNAs for NSD1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    NSD1 Human Pre-designed siRNA Set A
    NSD1 Human Pre-designed siRNA Set A
  • HY-RS25114
    Nsd1 Rat Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    Nsd1 Rat Pre-designed siRNA Set A contains three designed siRNAs for Nsd1 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Nsd1 Rat Pre-designed siRNA Set A
    Nsd1 Rat Pre-designed siRNA Set A
  • HY-W649594
    NR2F6 modulator-2

    		Orphan Nuclear Receptor Inflammation/Immunology Cancer
    NR2F6 modulator-2 (Compound I) is an autorepressed orphan nuclear receptor NR2F6 (Nuclear Receptor subfamily 2 group F member 6) modulator. NR2F6 modulator-2 can inhibits the recruitment of the bio-NSD1 peptide with an IC50 of 2.0 equivalents of NR2F6. NR2F6 modulator-2 can be used for the researches of cancer and immunology [1].
    NR2F6 modulator-2
  • HY-180553
    NSD2-IN-6

    		Histone Methyltransferase Cancer
    NSD2-IN-6 is a selective and orally active NSD2 inhibitor with IC50s of 3.8  and 274 nM for NSD2 and NSD1 respectively. NSD2-IN-6 reduces H3K36me2 levels, reverses cell plasticity by restoring the androgen receptor ( AR) signaling pathway. NSD2-IN-6 reduces a shift from cluster 2 and 3 states towards the cluster 1 state in organoids. NSD2-IN-6 exerts antitumor activity by reversing tumor cell plasticity, suppressing growth, and promoting apoptosis in vivo. NSD2-IN-6 can be used for prostate cancer research [1].
    NSD2-IN-6
  • HY-177400
    NSD-IN-5

    		Histone Methyltransferase Cancer
    NSD-IN-5 (Example 47) is a nuclear receptor-binding SET domain (NSD) inhibitor with IC5050 values ​​of 6 and < 1 nM for NSD1 and NSD2, respectively. NSD-IN-5 also exhibits inhibitory activity against Avg KMS11 cells with an IC5050 of 6 nM. NSD-IN-5 may be used in research on multiple myeloma [1].
    NSD-IN-5
  • HY-133567
    SET7-IN-DC21

    		Histone Methyltransferase Infection Cardiovascular Disease Metabolic Disease Inflammation/Immunology Cancer
    SET7-IN-DC21 is a selective, potent SET7 inhibitor (IC50 = 15.93 μM; KD = 18.00 μM). SET7-IN-DC21 has good selectivity for several other epigenetic targets, such as SUV39H1, G9a, NSD1, DOT1L and MOF. SET7-IN-DC21 can be used for the researches of cancer, infection, inflammation, metabolic and cardiovascular disease, such as breast cancer [1].
    SET7-IN-DC21

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: